Cipla Gears To Step In With Gx Kaletra Supplies For nCoV
Executive Summary
Over half a dozen generic versions of AbbVie's Kaletra, currently part of treatment guidelines in China for nCoV-2019, are already on the Indian market and drug maker Cipla says it can make available around 12 million tablets of the combination. India has meanwhile just confirmed its first case of the coronavirus infection.